S&P Futures
3,934.50 +35.00 (+0.90%) Dow Futures
31,523.00 +310.00 (+0.99%) Nasdaq Futures
11,906.50 +65.75 (+0.56%) Russell 2000 Futures
1,791.30 +19.10 (+1.08%) Crude Oil
111.14 +0.86 (+0.78%) Gold
1,857.00 +14.90 (+0.81%)
Phio Pharmaceuticals Corp. (PHIOW)
- Benzinga
Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells
Phio Pharmaceuticals Corp (NASDAQ: PHIO) presented new preclinical data showing that silencing BRD4 with PH-894 can improve the quality and potency of HER2-targeted CAR-T cells in a CAR-T expansion model. These new data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting. Related: Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation. Results showed that PH-894 reduced the expansion-associated production of BRD4 and BRD4-reg
- PR Newswire
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new preclinical data showing that silencing BRD4 with PH-894, a self-delivering RNAi INTASYL compound, can be used to improve the characteristics of CAR-T cell products during the activation and expansion phases of the cell manufacturing process. These new data will be presen
- PR Newswire
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.
